image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 35.03
-0.793 %
$ 1.71 B
Market Cap
-42.2
P/E
1. INTRINSIC VALUE

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes.[ Read More ]

The intrinsic value of one ATRC stock under the base case scenario is HIDDEN Compared to the current market price of 35 USD, AtriCure, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ATRC

image
FINANCIALS
399 M REVENUE
20.84%
-26.7 M OPERATING INCOME
37.47%
-30.4 M NET INCOME
34.49%
4.48 M OPERATING CASH FLOW
120.25%
21.8 M INVESTING CASH FLOW
-50.42%
-32 K FINANCING CASH FLOW
99.55%
116 M REVENUE
-0.31%
-7.4 M OPERATING INCOME
-3.31%
-7.85 M NET INCOME
1.94%
20 M OPERATING CASH FLOW
142.77%
4.39 M INVESTING CASH FLOW
-85.78%
-333 K FINANCING CASH FLOW
-16.70%
Balance Sheet Decomposition AtriCure, Inc.
image
Current Assets 266 M
Cash & Short-Term Investments 137 M
Receivables 52.5 M
Other Current Assets 76.5 M
Non-Current Assets 348 M
Long-Term Investments 0
PP&E 46.8 M
Other Non-Current Assets 301 M
Current Liabilities 74.6 M
Accounts Payable 27.4 M
Short-Term Debt 2.53 M
Other Current Liabilities 44.7 M
Non-Current Liabilities 73.2 M
Long-Term Debt 72 M
Other Non-Current Liabilities 1.23 M
EFFICIENCY
Earnings Waterfall AtriCure, Inc.
image
Revenue 399 M
Cost Of Revenue 98.9 M
Gross Profit 300 M
Operating Expenses 327 M
Operating Income -26.7 M
Other Expenses 3.76 M
Net Income -30.4 M
RATIOS
75.23% GROSS MARGIN
75.23%
-6.68% OPERATING MARGIN
-6.68%
-7.62% NET MARGIN
-7.62%
-6.53% ROE
-6.53%
-4.96% ROA
-4.96%
-5.14% ROIC
-5.14%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis AtriCure, Inc.
image
Net Income -30.4 M
Depreciation & Amortization 14.8 M
Capital Expenditures -42 M
Stock-Based Compensation 35.7 M
Change in Working Capital -18.2 M
Others -21.8 M
Free Cash Flow -37.5 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets AtriCure, Inc.
image
Wall Street analysts predict an average 1-year price target for ATRC of $41.5 , with forecasts ranging from a low of $26 to a high of $58 .
ATRC Lowest Price Target Wall Street Target
26 USD -25.78%
ATRC Average Price Target Wall Street Target
41.5 USD 18.47%
ATRC Highest Price Target Wall Street Target
58 USD 65.57%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership AtriCure, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
84.2 K USD 1
6-9 MONTHS
505 K USD 2
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
111 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
3 months ago
Aug 15, 2024
Sell 84.2 K USD
Yuen Maggie
Director
- 3500
24.07 USD
5 months ago
May 30, 2024
Bought 111 K USD
Privitera Salvatore
Chief Technical Officer
+ 5000
22.25 USD
6 months ago
May 01, 2024
Sell 36.1 K USD
Noznesky Justin J
Chief Mktg & Strategy Officer
- 1500
24.09 USD
7 months ago
Apr 01, 2024
Sell 45.6 K USD
Noznesky Justin J
Chief Mktg & Strategy Officer
- 1500
30.39 USD
8 months ago
Mar 18, 2024
Sell 60.6 K USD
Dahlquist Karl S.
Chief Legal Officer
- 1885
32.16 USD
8 months ago
Mar 12, 2024
Sell 55.1 K USD
Noznesky Justin J
Chief Mktg & Strategy Officer
- 1500
36.72 USD
8 months ago
Mar 05, 2024
Sell 308 K USD
Dahlquist Karl S.
Chief Legal Officer
- 8231
37.36 USD
1 year ago
Nov 01, 2023
Sell 43 K USD
Dahlquist Karl S.
Chief Legal Officer
- 1248
34.43 USD
1 year ago
Jul 26, 2023
Sell 195 K USD
Dahlquist Karl S.
Chief Legal Officer
- 3417
57.09 USD
1 year ago
Jun 08, 2023
Sell 34.1 K USD
Prange Karen
Director
- 713
47.89 USD
1 year ago
Jun 06, 2023
Sell 66.9 K USD
Dahlquist Karl S.
Chief Legal Officer
- 1422
47.03 USD
1 year ago
May 26, 2023
Sell 203 K USD
Yuen Maggie
Director
- 4313
47.04 USD
1 year ago
May 01, 2023
Sell 198 K USD
Dahlquist Karl S.
Chief Legal Officer
- 4417
44.83 USD
2 years ago
May 13, 2022
Sell 137 K USD
Austin Tonya
Chief Human Resources Officer
- 3203
42.69 USD
2 years ago
Apr 08, 2022
Sell 17.4 K USD
Austin Tonya
Chief Human Resources Officer
- 282
61.59 USD
2 years ago
Mar 04, 2022
Sell 95.3 K USD
Austin Tonya
Chief Human Resources Officer
- 1409
67.66 USD
2 years ago
Mar 02, 2022
Sell 229 K USD
Austin Tonya
Chief Human Resources Officer
- 3259
70.4 USD
2 years ago
Feb 11, 2022
Sell 169 K USD
Austin Tonya
Chief Human Resources Officer
- 2490
67.97 USD
2 years ago
Jan 14, 2022
Sell 180 K USD
Austin Tonya
Chief Human Resources Officer
- 2719
66.11 USD
2 years ago
Dec 10, 2021
Sell 108 K USD
Austin Tonya
Chief Human Resources Officer
- 1528
70.88 USD
3 years ago
Nov 12, 2021
Sell 215 K USD
Austin Tonya
Chief Human Resources Officer
- 2732
78.55 USD
3 years ago
Nov 04, 2021
Sell 221 K USD
Wirick Angela L
Chief Financial Officer
- 2604
85 USD
3 years ago
Nov 04, 2021
Sell 324 K USD
Collar Mark A
Director
- 4000
80.91 USD
3 years ago
Apr 30, 2021
Bought 2.61 K USD
GROVES REGINA E
Director
+ 34
76.68 USD
3 years ago
Oct 08, 2021
Sell 47.7 K USD
Austin Tonya
Chief Human Resources Officer
- 665
71.8 USD
3 years ago
Sep 15, 2021
Sell 236 K USD
GROVES REGINA E
Director
- 3156
74.73 USD
3 years ago
Sep 13, 2021
Sell 1.62 M USD
Seith Douglas J
Chief Operating Officer
- 21444
75.54 USD
3 years ago
Sep 10, 2021
Sell 94.7 K USD
Austin Tonya
Chief Human Resources Officer
- 1227
77.18 USD
3 years ago
Aug 13, 2021
Sell 236 K USD
Austin Tonya
Chief Human Resources Officer
- 3232
73.1 USD
3 years ago
Aug 09, 2021
Sell 571 K USD
Seith Douglas J
Chief Operating Officer
- 7065
80.79 USD
3 years ago
Aug 06, 2021
Sell 476 K USD
Wirick Angela L
Chief Financial Officer
- 5939
80.21 USD
3 years ago
Jul 30, 2021
Sell 749 K USD
Privitera Salvatore
Chief Technical Officer
- 8808
85 USD
3 years ago
Jul 28, 2021
Sell 660 K USD
Privitera Salvatore
Chief Technical Officer
- 8000
82.5 USD
3 years ago
Jul 20, 2021
Sell 160 K USD
Privitera Salvatore
Chief Technical Officer
- 2000
80 USD
3 years ago
Jul 16, 2021
Sell 38.5 K USD
Austin Tonya
Chief Human Resources Officer
- 493
78.03 USD
3 years ago
Jul 12, 2021
Sell 638 K USD
Doraiswamy Vinayak
Chief Scientific Officer
- 7672
83.12 USD
3 years ago
Jul 01, 2021
Sell 239 K USD
Collar Mark A
Director
- 3000
79.61 USD
3 years ago
Jul 01, 2021
Sell 26.7 K USD
Dahlquist Karl S.
Chief Legal Officer
- 336
79.53 USD
3 years ago
Jun 25, 2021
Sell 330 K USD
Noznesky Justin J
Chief Mktg & Strategy Officer
- 4119
80 USD
3 years ago
Jun 21, 2021
Sell 1.15 M USD
Noznesky Justin J
Chief Mktg & Strategy Officer
- 15000
76.36 USD
3 years ago
Jun 21, 2021
Sell 458 K USD
Noznesky Justin J
Chief Mktg & Strategy Officer
- 6000
76.36 USD
3 years ago
Jun 18, 2021
Sell 200 K USD
Austin Tonya
Chief Human Resources Officer
- 2620
76.36 USD
3 years ago
May 26, 2021
Sell 303 K USD
GROVES REGINA E
Director
- 4208
71.95 USD
3 years ago
May 07, 2021
Sell 3.01 M USD
Drake Scott William
Director
- 38641
77.9 USD
3 years ago
May 10, 2021
Sell 354 K USD
Drake Scott William
Director
- 4631
76.52 USD
3 years ago
May 03, 2021
Sell 389 K USD
WEHRWEIN SVEN
Director
- 5000
77.75 USD
3 years ago
May 03, 2021
Sell 391 K USD
WEHRWEIN SVEN
Director
- 5000
78.19 USD
3 years ago
Apr 01, 2021
Sell 196 K USD
Collar Mark A
Director
- 3000
65.28 USD
3 years ago
Apr 01, 2021
Sell 196 K USD
Collar Mark A
Director
- 3000
65.28 USD
5 years ago
Mar 06, 2019
Sell 219 K USD
Seith Douglas J
Chief Operating Officer
- 7500
29.25 USD
5 years ago
Mar 06, 2019
Sell 102 K USD
Seith Douglas J
Chief Operating Officer
- 3500
29.25 USD
3 years ago
Feb 12, 2021
Sell 1.62 M USD
CARREL MICHAEL H
President, CEO, & Director
- 25000
65 USD
3 years ago
Feb 10, 2021
Sell 1.58 M USD
CARREL MICHAEL H
President, CEO, & Director
- 25000
63 USD
3 years ago
Feb 11, 2021
Sell 1.6 M USD
CARREL MICHAEL H
President, CEO, & Director
- 25000
64 USD
3 years ago
Feb 08, 2021
Sell 1.52 M USD
CARREL MICHAEL H
President, CEO, & Director
- 25000
61 USD
3 years ago
Feb 09, 2021
Sell 1.55 M USD
CARREL MICHAEL H
President, CEO, & Director
- 25000
62 USD
3 years ago
Feb 02, 2021
Sell 896 K USD
Seith Douglas J
Chief Operating Officer
- 14941
60 USD
3 years ago
Feb 02, 2021
Sell 1.5 M USD
CARREL MICHAEL H
President, CEO, & Director
- 25000
60 USD
3 years ago
Jan 11, 2021
Sell 1.48 M USD
CARREL MICHAEL H
President, CEO, & Director
- 25000
59 USD
3 years ago
Jan 04, 2021
Sell 166 K USD
Collar Mark A
Director
- 3000
55.36 USD
3 years ago
Jan 04, 2021
Sell 804 K USD
Noznesky Justin J
SVP, Mktg & Business Develop
- 15000
53.57 USD
3 years ago
Jan 04, 2021
Sell 450 K USD
Noznesky Justin J
SVP, Mktg & Business Develop
- 8397
53.61 USD
3 years ago
Dec 28, 2020
Sell 1.45 M USD
CARREL MICHAEL H
President, CEO, & Director
- 24953
58 USD
3 years ago
Dec 21, 2020
Sell 1.36 M USD
CARREL MICHAEL H
President, CEO, & Director
- 24751
55 USD
3 years ago
Dec 22, 2020
Sell 1.42 M USD
CARREL MICHAEL H
President, CEO, & Director
- 25000
57 USD
3 years ago
Dec 22, 2020
Sell 1.4 M USD
CARREL MICHAEL H
President, CEO, & Director
- 25000
56 USD
3 years ago
Dec 17, 2020
Sell 1.28 M USD
CARREL MICHAEL H
President, CEO, & Director
- 25000
51 USD
3 years ago
Dec 17, 2020
Sell 1.25 M USD
CARREL MICHAEL H
President, CEO, & Director
- 25000
50 USD
3 years ago
Dec 17, 2020
Sell 1.3 M USD
CARREL MICHAEL H
President, CEO, & Director
- 25000
52 USD
3 years ago
Dec 18, 2020
Sell 2.69 M USD
CARREL MICHAEL H
President, CEO, & Director
- 50249
53.51 USD
3 years ago
Dec 17, 2020
Sell 547 K USD
Privitera Salvatore
Chief Technical Officer
- 10654
51.33 USD
3 years ago
Dec 17, 2020
Sell 931 K USD
Seith Douglas J
Chief Operating Officer
- 18617
50 USD
3 years ago
Dec 09, 2020
Sell 183 K USD
Privitera Salvatore
Chief Technical Officer
- 3846
47.5 USD
4 years ago
Nov 17, 2020
Bought 501 K USD
Drake Scott William
Director
+ 12350
40.54 USD
4 years ago
Oct 09, 2020
Sell 1.17 M USD
Seith Douglas J
Chief Operating Officer
- 29161
40.09 USD
4 years ago
Oct 06, 2020
Sell 93.2 K USD
Collar Mark A
Director
- 2330
40 USD
4 years ago
Oct 01, 2020
Sell 26.9 K USD
Collar Mark A
Director
- 670
40.2 USD
4 years ago
Sep 14, 2020
Sell 264 K USD
GROVES REGINA E
Director
- 6313
41.83 USD
4 years ago
Jul 01, 2020
Sell 178 K USD
Collar Mark A
Director
- 4000
44.6 USD
4 years ago
May 11, 2020
Sell 1.15 M USD
CARREL MICHAEL H
President, CEO, & Director
- 25000
46 USD
4 years ago
May 12, 2020
Sell 1.18 M USD
CARREL MICHAEL H
President, CEO, & Director
- 25000
47 USD
4 years ago
May 08, 2020
Sell 1.12 M USD
CARREL MICHAEL H
President, CEO, & Director
- 25000
45 USD
4 years ago
Apr 17, 2020
Sell 400 K USD
Noznesky Justin J
SVP, Mktg & Business Develop
- 10000
40 USD
4 years ago
Apr 17, 2020
Sell 400 K USD
Noznesky Justin J
SVP, Mktg & Business Develop
- 10000
40 USD
4 years ago
Apr 07, 2020
Sell 144 K USD
Collar Mark A
Director
- 4000
36.07 USD
4 years ago
Apr 07, 2020
Sell 350 K USD
Noznesky Justin J
SVP, Mktg & Business Develop
- 10000
35 USD
4 years ago
Feb 21, 2020
Sell 592 K USD
Wade M. Andrew
CFO
- 15000
39.45 USD
4 years ago
Feb 21, 2020
Sell 592 K USD
Wade M. Andrew
CFO
- 15000
39.46 USD
4 years ago
Feb 14, 2020
Sell 1.1 M USD
CARREL MICHAEL H
President, CEO, & Director
- 25000
44 USD
4 years ago
Feb 13, 2020
Sell 1.08 M USD
CARREL MICHAEL H
President, CEO, & Director
- 25000
43 USD
4 years ago
Feb 10, 2020
Sell 1.02 M USD
CARREL MICHAEL H
President, CEO, & Director
- 25000
41 USD
4 years ago
Feb 11, 2020
Sell 1.05 M USD
CARREL MICHAEL H
President, CEO, & Director
- 25000
42 USD
4 years ago
Jan 29, 2020
Sell 1 M USD
CARREL MICHAEL H
President, CEO, & Director
- 25000
40 USD
4 years ago
Jan 16, 2020
Sell 917 K USD
Seith Douglas J
Chief Operating Officer
- 25471
36 USD
4 years ago
Jan 16, 2020
Sell 360 K USD
Wade M. Andrew
SVP and CFO
- 10000
36 USD
4 years ago
Jan 15, 2020
Sell 140 K USD
Collar Mark A
Director
- 4000
35.02 USD
4 years ago
Jan 14, 2020
Sell 340 K USD
Wade M. Andrew
SVP and CFO
- 10000
34 USD
4 years ago
Jan 14, 2020
Sell 1.24 M USD
Seith Douglas J
Chief Operating Officer
- 36363
34 USD
4 years ago
Jan 14, 2020
Sell 850 K USD
CARREL MICHAEL H
President, CEO, & Director
- 25000
34 USD
4 years ago
Jan 15, 2020
Sell 875 K USD
CARREL MICHAEL H
President, CEO, & Director
- 25000
35 USD
4 years ago
Jan 02, 2020
Sell 777 K USD
CARREL MICHAEL H
President, CEO, & Director
- 23546
33 USD
4 years ago
Jan 02, 2020
Sell 493 K USD
Noznesky Justin J
SVP, Mktg & Business Develop
- 15000
32.89 USD
4 years ago
Jan 02, 2020
Sell 465 K USD
Noznesky Justin J
SVP, Mktg & Business Develop
- 14134
32.89 USD
4 years ago
Dec 26, 2019
Sell 32 K USD
Wade M. Andrew
SVP and CFO
- 1000
32 USD
4 years ago
Dec 26, 2019
Sell 1.01 M USD
Seith Douglas J
Chief Operating Officer
- 31440
32 USD
4 years ago
Nov 25, 2019
Sell 351 K USD
Wade M. Andrew
SVP and CFO
- 11705
30 USD
5 years ago
Sep 16, 2019
Sell 1.12 M USD
Seith Douglas J
Chief Operating Officer
- 43569
25.65 USD
5 years ago
Sep 16, 2019
Sell 134 K USD
Seith Douglas J
Chief Operating Officer
- 5235
25.51 USD
5 years ago
Sep 12, 2019
Bought 12.4 K USD
GROVES REGINA E
Director
+ 500
24.86 USD
5 years ago
Jul 31, 2019
Sell 48 K USD
CARREL MICHAEL H
President, CEO, & Director
- 1454
33 USD
5 years ago
Jul 10, 2019
Sell 800 K USD
CARREL MICHAEL H
President, CEO, & Director
- 25000
32 USD
5 years ago
Jun 17, 2019
Sell 300 K USD
Noznesky Justin J
SVP, Mktg & Business Develop
- 10000
30 USD
5 years ago
Jun 04, 2019
Sell 21.1 K USD
Wade M. Andrew
SVP and CFO
- 704
30 USD
5 years ago
Jun 05, 2019
Sell 303 K USD
Wade M. Andrew
SVP and CFO
- 10107
30 USD
5 years ago
Apr 30, 2019
Sell 450 K USD
Noznesky Justin J
SVP, Mktg & Business Develop
- 15000
30 USD
5 years ago
Apr 30, 2019
Sell 296 K USD
Wade M. Andrew
SVP and CFO
- 9850
30 USD
5 years ago
Apr 15, 2019
Sell 347 K USD
Noznesky Justin J
SVP, Mktg & Business Develop
- 12569
27.64 USD
6 years ago
Aug 15, 2018
Sell 121 K USD
Noznesky Justin J
SVP, Mktg & Business Develop
- 4000
30.32 USD
6 years ago
Jun 14, 2018
Sell 52.2 K USD
Collar Mark A
Director
- 2090
25 USD
6 years ago
May 15, 2018
Sell 92.2 K USD
Noznesky Justin J
SVP, Mktg & Business Develop
- 4000
23.05 USD
6 years ago
May 08, 2018
Sell 228 K USD
Krell Elizabeth D
Director
- 10000
22.82 USD
6 years ago
Mar 13, 2018
Sell 200 K USD
Krell Elizabeth D
Director
- 10000
20 USD
6 years ago
Mar 01, 2018
Bought 194 K USD
Drake Scott William
Director
+ 11000
17.64 USD
6 years ago
Mar 01, 2018
Bought 17.4 K USD
GROVES REGINA E
Director
+ 1000
17.43 USD
6 years ago
Feb 15, 2018
Sell 68.1 K USD
Noznesky Justin J
SVP, Mktg & Business Develop
- 4000
17.03 USD
6 years ago
Nov 30, 2017
Sell 36.8 K USD
Wade M. Andrew
SVP and CFO
- 2000
18.41 USD
7 years ago
Nov 08, 2017
Bought 27.5 K USD
JOHNSON B KRISTINE
Director
+ 1500
18.36 USD
7 years ago
Aug 22, 2017
Sell 224 K USD
Krell Elizabeth D
Director
- 10000
22.4 USD
7 years ago
Jun 13, 2017
Sell 1.24 M USD
Seith Douglas J
Chief Operating Officer
- 58112
21.39 USD
7 years ago
May 17, 2017
Sell 214 K USD
Krell Elizabeth D
Director
- 10000
21.44 USD
7 years ago
May 05, 2017
Sell 221 K USD
Hooven Michael D
Director
- 10000
22.08 USD
7 years ago
Mar 17, 2017
Sell 377 K USD
LUX ANDREW L
SVP, Ops & Quality
- 20000
18.85 USD
12 years ago
Mar 13, 2012
Sell 35.1 K USD
Hooven Michael D
Director
- 3500
10.02 USD
7 years ago
Dec 07, 2016
Sell 94.6 K USD
LUX ANDREW L
SVP, Ops & Quality
- 5038
18.77 USD
7. News
AtriCure, Inc. (ATRC) Q3 2024 Earnings Call Transcript AtriCure, Inc. (NASDAQ:ATRC ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lilia Lozada - JPMorgan Mike Matson - Needham Danielle Antalffy - UBS Suraj Kalia - Oppenheimer & Co. Operator Good afternoon. And welcome to AtriCure's Third Quarter 2024 Earnings Conference Call. seekingalpha.com - 2 weeks ago
AtriCure (ATRC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 2 weeks ago
AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates AtriCure (ATRC) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.20 per share a year ago. zacks.com - 2 weeks ago
AtriCure Reports Third Quarter 2024 Financial Results MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2024 financial results. “Our broad-based growth in the third quarter reflects strong, ongoing adoption trends throughout our business,” said Michael Carrel, President and Chief Executive Officer at AtriCure. “During the quarter, we launched sev. businesswire.com - 2 weeks ago
AtriCure's Stock Rises After Launch of cryoSPHERE MAX Device ATRC's cryoSPHERE MAX probe cuts freeze times by 50%, advancing Cryo Nerve Block therapy to improve post-op pain relief and reduce opioid dependency risks. zacks.com - 1 month ago
AtriCure Announces Launch of cryoSPHERE MAX™ Probe for Post-Operative Pain Management MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE MAX™ cryoablation probe. The cryoSPHERE MAX probe features a larger ball tip designed to optimize Cryo Nerve Block™ therapy (cryoNB). The new probe reduces freeze times by 50% when compared to AtriCure's first generation. businesswire.com - 1 month ago
AtriCure Gets CE Mark for EnCompass Clamp, Expands in Europe ATRC's EnCompass Clamp receives a CE Mark, enabling European surgeons to access faster, simpler heart ablation in cardiac surgeries with advanced radiofrequency technology. zacks.com - 1 month ago
AtriCure to Announce Third Quarter 2024 Financial Results MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2024 financial results on Tuesday, October 29, 2024. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, October 29, 2024, to discuss its third quarter 2024 financial results. Those interested in. businesswire.com - 1 month ago
Faisal Al Bannai In 2023, the Advanced Technology Research Council (ATRC), an arm of the Abu Dhabi government, spent millions of dollars building a series of large language models. ATRC secretary general Faisal Al Bannai then decided to release them online for free, reasoning that if they were as good as the team’s internal testing showed, it would… time.com - 2 months ago
AtriCure's Shares Likely to Benefit From New AtriClip Device Sales ATRC announces the treatment of the first patient using the AtriClip FLEX-Mini device. zacks.com - 2 months ago
AtriCure Announces that the First Patient has been Treated with the Revolutionary AtriClip® FLEX-Mini™ Device MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the first patient was treated with the AtriClip® FLEX-Mini™ device, which recently received 510(k) clearance. The AtriClip FLEX-Mini sets a new standard as the smallest profile surgical LAA device on the market and builds upon the proven technology of. businesswire.com - 2 months ago
AtriCure's (ATRC) AtriClip Receives Expanded CE-Mark Indication AtriCure (ATRC) announces the receipt of an expanded CE-Mark indication for its AtriClip devices for reducing strokes in patients with Afib. zacks.com - 2 months ago
8. Profile Summary

AtriCure, Inc. ATRC

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 1.71 B
Dividend Yield 0.00%
Description AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Contact 7555 Innovation Way, Mason, OH, 45040 https://www.atricure.com
IPO Date Aug. 5, 2005
Employees 1200
Officers Mr. Douglas J. Seith Chief Operating Officer Valerie Storch-Willhaus Vice President of Corporate Marketing & Communications Dr. Vinayak Doraiswamy Ph.D. Chief Scientific Officer Mr. Justin J. Noznesky Chief Marketing & Strategy Officer Ms. Deborah Yount Chief Human Resources Officer Mr. Karl S. Dahlquist CCEP, J.D. Chief Legal Officer Ms. Angela L. Wirick CPA Chief Financial Officer Mr. Salvatore Privitera J.D. Chief Technical Officer Mr. Michael H. Carrel Chief Executive Officer, President & Director